Skip to main content

Bevacizumab

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • RegistryNCT01269853
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionGlioblastoma Multiforme
  • SponsorNorthwell Health
How Bevacizumab worksNCT012698531 min

What the film says

Read the transcript

Glioblastoma returns in essentially every patient. At recurrence, bevacizumab is given by vein to starve the tumor of blood vessels, but the brain's barrier lets little of it through.

The idea: skip the barrier. Thread a catheter to the artery feeding the tumor, open the barrier briefly, and deliver the drug there.

At Lenox Hill in New York, neurosurgeons pass a microcatheter from the groin into the cerebral artery supplying the tumor, infuse mannitol to loosen the blood-brain barrier for minutes, then deliver bevacizumab straight in. An earlier trial showed one such dose was safe. This study repeats it at each progression, with or without intravenous dosing between.

John Boockvar leads it, for relapsed glioblastoma and anaplastic astrocytoma. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT01269853

    All patients recur; GBM median OS 9–12 months; IV bevacizumab standard at recurrence; BBB penetration uncertain; Super-selective intra-arterial cerebral infusion (SIACI); mannitol to open BBB; 15 mg/kg; Prior phase I: single SIACI dose safe (+2 more lines)

The drug

What is being tested.

Experimental portion of this proposal: This trial will have two experimental arms that will be open labeled and non-randomized. ARM 1 (If the patient has multifocal disease or leptomeningeal disease) Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan. If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and…

ARM 2 (If the patient has no multifocal disease or leptomeningeal disease) Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle

The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%. At that point, these patients are deemed treatment failures and are given another treatment.

The study

How the trial runs.

The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of either surgical resection, external beam radiation or both.

All patients experience a recurrence after first-line therapy, so improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. It is unknown if currently used intravenous (IV) therapies even cross the blood brain barrier (BBB).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • 18 years of age or older.
  • Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).
  • Patients must have at least one confirmed and evaluable tumor site. A confirmed tumor site is one in which is biopsy-proven.
  • Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2).
  • Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.